Sonnet BioTherapeutic News

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20

BenzingaDec 20 06:30 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaDec 20 06:29 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 23 11:37 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaMay 28 06:52 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaMay 16 14:27 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaFeb 15 12:33 ET

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksJan 7 05:47 ET

Sonnet BioTherapeutics Holdings (SONN) Gets a Buy From BTIG

TipRanksJan 2 09:49 ET

Ladenburg Thalmann Initiates Coverage On Sonnet BioTherapeutics With Buy Rating, Announces Price Target of $7

BenzingaNov 27, 2023 09:00 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaNov 27, 2023 08:59 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 23, 2023 04:36 ET

Sonnet BioTherapeutics Analyst Ratings

BenzingaAug 16, 2023 10:22 ET

Chardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksAug 16, 2023 09:35 ET

Chardan Cuts Price Target on Sonnet BioTherapeutics to $12 From $14, Keeps Buy Rating

MT NewswiresAug 16, 2023 09:32 ET

Sonnet BioTherapeutics Holdings (SONN) Receives a Buy From EF Hutton

TipRanksJun 26, 2023 12:25 ET

EF Hutton Reiterates Buy on Sonnet BioTherapeutics, Maintains $6.7 Price Target

BenzingaJun 26, 2023 09:13 ET

Chardan Lowers Price Target on Sonnet BioTherapeutics to $14 From $17, Keeps Buy Rating

MT NewswiresMay 11, 2023 06:23 ET

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14

BenzingaMay 11, 2023 05:21 ET

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $17

BenzingaApr 19, 2023 06:23 ET

EF Hutton Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

TipRanksFeb 15, 2023 07:35 ET